New Opportunities to Improve Management of Patients with or at High Risk of ASCVD Events

This symposium will address reducing ASCVD event risk with adjunctive therapies to statin use.
This symposium will address reducing ASCVD event risk with adjunctive therapies to statin use.
Enroll in this meeting
October 25, 2019
11:30 AM - 01:15 PM EDT
Hilton Baltimore Inner Harbor Hotel
401 West Pratt Street, Holiday Ballroom, Baltimore, Maryland, United States
Enrollment Fee: Free
Free
  • Overview

    This 75-minute, highly interactive symposium will feature a faculty of 2 leading experts who will address reducing ASCVD event risk with adjunctive therapies to statin use. This educational activity will provide the opportunity for the faculty and symposium participants to work through complex issues that challenge healthcare providers in caring for patients with elevated atherogenic cholesterol and triglycerides and diabetes, many of whom have been sub-optimally managed and continue to be at risk of advancing cardiovascular disease.

  • Agenda

    11:30 am

    Registration and Buffet Lunch

    12:00 pm

    Program Overview

    12:05

    New Cholesterol Guidelines: What You Should Know

    12:20

    Update on Cardiovascular Outcomes Trials of Adjunctive Therapies to Statins

    12:40

    Omega-3 FAs and Their Use in Patients with ASCVD

    12:55

    Case Presentations on Primary and Secondary Prevention

    1:10

    Closing Comments

    1:15 pm

    Adjourn

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Have greater clarity on implementing the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
    • Describe the spectrum of major recent ASCVD randomized cardiovascular outcomes trials
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Apply evidence-based guidelines and recent randomized clinical trial evidence to lifestyle and therapeutic approaches for managing patients at high risk of cardiovascular events
  • Accreditation & Credit Designation

    The AOA Bureau of OMED is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. The AOA Bureau of OMED designates this live program activity for a maximum of 1.25 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.

  • Commercial Support

    Supported by an independent educational grant from Amarin Pharma, Inc.

Facebook Comments

Sign up for the Medtelligence newsletters.
Comprehensive Cardiology Education.

Better education for a better you.

* Required
Optional
Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free